HugoScore hugoscore.org

Mental health AI

Wysa

Wysa’s consumer self-help, institutional referral, and clinician-linked channels have different authority and data-sharing arrangements. This profile distinguishes those channels. The former combined score of 55 is historical, rather than a current score for every deployment.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Mixed5 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Mixed 5 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Wysa app: consumer AI Conversation Space (chatbot with third-party LLMs), institutional Digital Front Door and Digital Referral Assistant, and clinician-linked services (Coach, Medical Assistant, Co-Pilot). Operator identity (Touchkin eServices Pvt. Ltd. / Wysa Ltd.) and reporting to institutions differ by service.

Initial Anthropic coding has an Anthropic model in the role record. Astra review conflicted: OpenAI model in role record.

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • Q9 covers the combined consumer and institutional scope. A consumer-only assessment could differ.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Confirmed at document level
You are interacting with an AI software when using our AI services, and not a person. Source

Global Privacy Policy v7.2.2 (revised 2026-10-16). The Terms also describe LLM-enabled AI.

2. Operator and model maker namedYesdocumented
Confirmed at document level
OpenAI, Anthropic LLM, Google Gemini LLM Source

Wysa's service provider list names these LLM providers for Wysa apps that provision generative AI. The privacy policy names Touchkin eServices Pvt. Ltd. as 'makers of the Wysa app and its services' and the controller or processor role varies by Institution.

3. Patient chooses to use itNodeployer-dependent
Confirmed at document level
We will work with your public institution, healthcare institution, educational institution or other organization to offer our services. Source

Conversation Space is chosen by the user in the consumer app, but Digital Front Door, referral and clinician-linked services are Institution-arranged. Answer is for the whole function.

4. Patient sets the taskNodocumented
Confirmed at document level
This allows you to control how you want the AI to converse with you. Source

The user controls tone through the bot persona. The Conversation Space follows a decision-tree with clinician-written content, and recommendations come from Wysa's closed care library.

5. Patient can decline or stopNodeployer-dependent
Confirmed at document level
Before you can use these Institutional services, you will need to agree to our notices and to the notices of your Institution. Source

The consumer app can be stopped, but access to institutional services depends on the Institution agreement and a right to decline AI while keeping the same service is not documented.

6. Patient sees the AI outputYesdocumented
Confirmed at document level
These reports give you personalized and useful information based on how you use the app. Source

The user sees chat responses and weekly LLM-generated insight reports.

7. Patient can correct or challengeYesdocumented
Confirmed at document level
We change our conversation anytime you inform us that the AI is not helping. Source

Documented under 'Automated Decisions'. The policy also gives a 'Fix It' right to correct personal data. No formal appeal of an AI response is described.

8. Patient can get a copyYesdocumented
Confirmed at document level
Get a Copy: You can ask for a copy of the personal data we have about you. Source

Also 'Send It Elsewhere' for transfer of personal data.

9. Patient can deleteNodeployer-dependent
Corrected after independent review; accepted by editor
Co-pilot service will not be deleted Source

For the combined consumer and institutional scope, reset excludes Medical Assistant/Co-Pilot data and retention remains institution-controlled. Consumer conversation deletion alone would qualify.

10. Training or sale does not override patient choiceNodocumented
Confirmed at document level
This preference data may be used to improve the app's AI conversational models in aggregate and anonymized form. Source

Documented use of persona preference data for Wysa's own models. The same policy says conversation messages are not used as training data by the LLM provider and that the AI does not learn on its own. 'Object' rights exist but aggregate anonymized data is outside them.

11. Patient can run it or take it elsewhereNodocumented
Confirmed at document level
Send It Elsewhere: You can ask us to send your personal data to someone else electronically. Source

Export only. Vendor-hosted and proprietary, so no way to run it or move the function without Wysa.

12. No advertising or data businessNodocumented
Confirmed at document level
We use Meta Ads Manager to make ads about our service, to send these ads, and to see how well they are doing. Source

Policy section on campaigns and promotions. It also says 'We do not share or sell your information, messages, or how you use our apps to advertisers or companies that buy data', and shares aggregated analytics with Institutions. Judgment call for the reviewer: the documented Meta advertising and cohort analysis of 'users' is why this is no.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

MixedEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Mixed, channel-dependent

Legacy editorial placement, pre-method: 55

No eligible reviewer. This tool uses AI models from both companies whose models code HugoScore reviews, Anthropic and OpenAI, so neither may review it. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Wysa serve in this deployment?
Control Wysa app: consumer AI Conversation Space (chatbot with third-party LLMs), institutional Digital Front Door and Digital Referral Assistant, and clinician-linked services (Coach, Medical Assistant, Co-Pilot). Operator identity (Touchkin eServices Pvt. Ltd. / Wysa Ltd.) and reporting to institutions differ by service.
Agency read Mixed
Vendor
Wysa (Touchkin eServices Pvt. Ltd. / Wysa Ltd.)
Who it serves
Multiple consumer and institution-directed deployments
Primary User
Consumer users, institutional referrals, and clinician-linked users in distinct channels
Control Model
Consumer vendor-hosted, institution-linked and clinician-linked channels with distinct conditions.
Patient Impact
Exercises can support reflection and action. Clinical improvement is not a substitute for user control over routing, and formal data rights do not establish a direct appeal against a clinical decision.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Moderate for documented service distinctions (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 55

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 55. Not comparable with v1.3 positions.

Mixed, channel-dependent

Wysa’s consumer self-help, institutional referral, and clinician-linked channels have different authority and data-sharing arrangements. This profile distinguishes those channels. The former combined score of 55 is historical, rather than a current score for every deployment.

Patient agency

How this tool changes agency

Expands agency when

Exercises can support reflection and action. Clinical improvement is not a substitute for user control over routing, and formal data rights do not establish a direct appeal against a clinical decision.

Limits agency when

Actual institutional signup notices, alternatives and review routes require deployment evidence

Patient agency assessment

Who sets and changes the goal?

Patient authority

Self-help users can redirect conversation. Institutional pathways constrain the offered resources, but the policy does not establish that the AI itself denies care or that declining it loses access.

What can the patient understand, question, or do?

Critical capacity

Exercises can support reflection and action. Clinical improvement is not a substitute for user control over routing, and formal data rights do not establish a direct appeal against a clinical decision.

Can the patient evaluate the conditions of use?

Informed control

Nickname-based consumer use must not imply anonymity across referral, WhatsApp or clinical deployments. External LLM no-training statements do not cover all internal improvement uses.

Text findings

Conditions of use

Published controls and their limits

Nickname-based consumer use must not imply anonymity across referral, WhatsApp or clinical deployments. External LLM no-training statements do not cover all internal improvement uses.

What remains unknown?

Not tested or not established

Actual institutional signup notices, alternatives and review routes require deployment evidence

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Actual institutional signup notices, alternatives and review routes require deployment evidence No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Moderate for documented service distinctions (AI-assisted draft)